-
1.发明公开Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent 审中-公开Krebsbehandlung mitAntikörperngegen ERBB2和einem chemotherapeutischen Mittel
公开(公告)号：EP1947119A2
公开(公告)日：2008-07-23
申请号：EP08002425.0
申请日：1998-12-10
申请人： Genentech, Inc.
IPC分类号： C07K16/32 , A61K39/395 , A61K31/335
CPC分类号： C07K16/32 , A61K38/00 , A61K39/39558 , A61K2039/505 , C07K2317/24 , A61K2300/00
摘要： The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.
摘要翻译： 本发明涉及以ErbB2过度表达为特征的疾病的治疗。 更具体地，本发明涉及用抗ErbB2抗体和除蒽环类化合物之外的化学治疗剂的组合治疗对过度表达ErbB2的癌细胞敏感或诊断的人类患者。 多柔比星或表柔比星。
-
公开(公告)号：EP2275450A1
公开(公告)日：2011-01-19
申请号：EP10177992.4
申请日：1998-12-10
申请人： Genentech, Inc.
IPC分类号： C07K16/32 , A61K39/395
CPC分类号： A61K31/337 , A61K31/7068 , A61K38/00 , A61K39/395 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/32 , C07K2317/24 , A61K31/335 , A61K2300/00
摘要： The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.
摘要翻译： 本发明涉及以ErbB2过度表达为特征的疾病的治疗。 更具体地，本发明涉及用抗ErbB2抗体和除蒽环类化合物之外的化学治疗剂的组合治疗对过度表达ErbB2的癌细胞敏感或诊断的人类患者。 多柔比星或表柔比星。
-
3.发明公开Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent 审中-公开用针对ERBB2和化学治疗剂治疗癌症
公开(公告)号：EP1947119A3
公开(公告)日：2012-12-19
申请号：EP08002425.0
申请日：1998-12-10
申请人： Genentech, Inc.
IPC分类号： C07K16/32 , A61K39/395
CPC分类号： C07K16/32 , A61K38/00 , A61K39/39558 , A61K2039/505 , C07K2317/24 , A61K2300/00
摘要： The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.
-
公开(公告)号：EP2277919A1
公开(公告)日：2011-01-26
申请号：EP10178009.6
申请日：1998-12-10
申请人： Genentech, Inc.
IPC分类号： C07K16/32 , A61K39/395
CPC分类号： A61K31/337 , A61K31/7068 , A61K38/00 , A61K39/395 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/32 , C07K2317/24 , A61K31/335 , A61K2300/00
摘要： The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and gemcitabine.
摘要翻译： 本发明涉及以ErbB2过度表达为特征的疾病的治疗。 更具体地说，本发明涉及用抗ErbB2抗体和吉西他滨的组合治疗易患或诊断为过度表达ErbB2的癌症的人类患者。
-
-
-
搜索结果
4 条记录 (耗时 0.009 秒)
